Pharmaceutical Quality Control: How Drug Quality Is Built and Tested

Pharmaceutical quality control is often associated with the laboratory: raw materials are tested, samples are analyzed, results are compared with specifications, and finished products are released only after meeting established requirements.

That laboratory work is essential. But pharmaceutical quality is much larger than the final test result.

A tablet, capsule, injection, or other medicine reaches the QC laboratory after a long chain of controlled activities involving materials, suppliers, equipment, manufacturing processes, analytical methods, trained personnel, documentation, and quality systems. A passing laboratory result provides important evidence about the tested sample, but it does not replace the controls that produced that sample.

This is why pharmaceutical quality control should be understood as one part of a broader pharmaceutical quality system rather than as the point where quality is created.

Quick Summary

• Pharmaceutical quality control provides analytical evidence that materials and products meet established specifications.
• QC testing is essential, but testing is not a substitute for a controlled manufacturing process.
• Supplier qualification and raw-material controls are part of building pharmaceutical quality.
• Equipment must be appropriately qualified, maintained, and calibrated where applicable.
• Process validation and in-process controls help demonstrate that manufacturing processes can consistently produce the intended quality.
• OOS and OOT results require appropriate investigation rather than simply repeating a test until a passing result appears.
• CAPA should address root causes and its effectiveness should be evaluated.
• Quality risk management helps identify and control potential sources of quality risk before they become failures.
• PQR and process-performance data can support continual improvement.
• QA and QC are related but different functions within the wider pharmaceutical quality system.
• ICH Q10 provides a lifecycle model for a pharmaceutical quality system covering areas such as process performance and product quality monitoring, CAPA, change management, and management responsibility.

What Is Pharmaceutical Quality Control?

Pharmaceutical quality control is the part of the quality system concerned with activities such as sampling, specifications, testing, documentation, and release-related assessment of materials and products.

In practical terms, QC may be involved in testing:

• Active pharmaceutical ingredients (APIs)
• Excipients
• Packaging materials
• In-process materials
• Finished pharmaceutical products
• Stability samples
• Water and other relevant utilities or materials, depending on the manufacturing operation

Testing can involve chemical, physical, microbiological, instrumental, or other scientifically appropriate methods depending on the product and its specifications.

The purpose is not simply to generate numbers.

A QC result should provide reliable information that can be evaluated against an approved specification or other established requirement. The quality of that information therefore depends not only on the analytical method but also on sampling, sample handling, instrument suitability, analyst competence, reference standards, laboratory controls, data integrity, and documented procedures.

WHO GMP describes quality control as part of the overall system used to ensure pharmaceutical products are consistently produced and controlled to appropriate quality standards.

What Does QC Testing Actually Tell Us?

Suppose a finished tablet is tested for assay and the result falls within the approved specification.

That result is important.

It tells us that the tested sample, under the specified analytical procedure, produced a result meeting the established requirement.

But it does not independently prove that every tablet in the batch has exactly the same characteristics.

That is why pharmaceutical manufacturing relies on more than final-product testing.

Sampling plans, validated manufacturing processes, in-process controls, environmental controls where applicable, equipment qualification, process monitoring, documentation, and other GMP controls work together to provide confidence that the batch has been manufactured consistently.

This distinction is one of the most important concepts in pharmaceutical quality control.

QC testing provides evidence of quality; it does not create quality after manufacturing has already occurred.

How Pharmaceutical Quality Is Built Before QC Testing

The quality of a finished medicine is influenced long before the finished-product sample reaches the laboratory.

1. Supplier and Raw-Material Qualification

A pharmaceutical manufacturer may receive an API or excipient with a Certificate of Analysis (CoA), but a CoA should not be viewed as the entire supplier-qualification process.

A CoA provides analytical information for a particular material or batch. Supplier qualification addresses a broader question:

Can this supplier consistently provide material that meets the required quality standards?

Depending on the material, risk, supplier history, and applicable quality system, qualification activities may include review of specifications, quality documentation, manufacturing controls, audit findings, regulatory status, previous performance, deviations, complaints, and other relevant information.

The same principle applies to packaging materials and other critical inputs.

A reliable pharmaceutical quality system therefore looks beyond a single document and evaluates the controls supporting the material’s quality.

2. Product and Process Development

Quality is also influenced during development.

The formulation, manufacturing process, dosage form, critical material attributes, critical process parameters, analytical methods, and product specifications need to be developed with the intended product quality in mind.

For example, depending on the dosage form, development may involve understanding characteristics such as:

• Identity and purity
• Assay
• Impurities
• Dissolution
• Stability
• Physical properties
• Microbiological quality where applicable
• Bioavailability or bioequivalence considerations where relevant

ICH Q8(R2) places pharmaceutical development within the broader objective of designing a product and manufacturing process capable of consistently delivering the intended performance.

That concept is important because a robust product is not created by waiting until commercial production and then relying entirely on finished-product testing.

Equipment Must Be Suitable for Its Intended Use

Pharmaceutical manufacturing and QC laboratories depend heavily on equipment.

Manufacturing equipment must be suitable for its intended process, while laboratory instruments must be capable of producing reliable measurements under defined conditions.

Qualification, calibration, maintenance, and appropriate verification therefore become important parts of the quality system.

Consider a laboratory balance.

A result calculated from an inaccurately functioning balance can affect the preparation of standards, samples, reagents, or other materials used during analysis. Similarly, instruments such as pH meters, conductivity meters, chromatographic systems, dissolution apparatus, and other analytical equipment require controls appropriate to their intended use.

The exact qualification, calibration, verification, and maintenance requirements depend on the equipment and its application.

The principle remains straightforward:

Reliable analytical results require suitable equipment and controlled measurement systems.

Process Validation: Quality Cannot Depend Only on the Final Test

A successful finished-product test does not make an uncontrolled manufacturing process acceptable.

Consider a tablet manufacturing process.

Before the finished tablets reach QC, several stages may already have influenced their quality:

Dispensing → granulation → drying → milling → blending → compression → coating → packaging

At different stages, appropriate in-process controls can provide information about whether the process is operating as intended.

During compression, for example, relevant checks may include tablet weight, hardness, thickness, friability, disintegration, or other established attributes depending on the product and approved process controls.

These checks do not replace finished-product testing.

Instead, they provide information about the process while manufacturing is taking place.

Process validation adds another layer of assurance by demonstrating, through appropriate evidence, that a process is capable of consistently producing a product meeting predetermined requirements.

WHO GMP identifies validation and qualification as important components of pharmaceutical manufacturing controls.

The practical lesson is important:

A process should not be considered reliable simply because one finished batch passed QC testing.

OOS and OOT: When QC Results Raise a Question

QC laboratories sometimes generate results that require investigation.

Two terms that frequently appear in pharmaceutical quality discussions are Out of Specification (OOS) and Out of Trend (OOT).

An OOS result is a result that falls outside an approved specification.

For example, suppose an assay specification is 90–110%. A scientifically valid result of 88% would be outside that specification and would require appropriate handling under the site’s approved OOS procedure.

An OOT result is different.

A result can remain within specification but show an unusual departure from the established historical pattern. For example, repeated batches may historically produce results within a relatively narrow range, while a new result moves substantially away from that pattern without exceeding the formal specification.

An OOT signal can therefore provide an opportunity to investigate developing variation before it becomes an actual specification failure.

The investigation should not be treated as an exercise in finding a way to make an unwanted result disappear.

The objective is to understand what happened.

Laboratory factors may need to be assessed first, followed by manufacturing and other relevant factors when appropriate. The investigation should be scientifically justified and documented.

CAPA Should Solve Problems, Not Close Paperwork

Corrective and Preventive Action, commonly called CAPA, becomes important when an investigation identifies a root cause or systemic issue requiring corrective action.

Suppose an investigation identifies an analyst training issue.

Retraining may be part of the corrective action.

But suppose the investigation identifies a recurring equipment problem, material issue, inadequate procedure, or manufacturing-process weakness. In that case, simply retraining the analyst would not address the actual root cause.

Effective CAPA should therefore be connected to the identified cause.

More importantly, CAPA should not necessarily end when the action is implemented.

Effectiveness checking asks whether the action actually worked.

That distinction matters because a closed CAPA is not automatically an effective CAPA.

Quality Risk Management Helps Prevent Problems

Pharmaceutical quality should not depend entirely on reacting to failures after they occur.

Quality risk management provides a systematic way to assess, control, communicate, and review risks to pharmaceutical quality throughout the product lifecycle.

ICH Q9(R1) states that quality-risk decisions should be based on scientific knowledge and ultimately linked to patient protection, while the level of effort and formality should be proportionate to the level of risk.

In practical manufacturing, risk assessment can be relevant to areas such as:

• Raw-material selection
• Supplier qualification
• Manufacturing-process design
• Equipment selection
• Cross-contamination controls
• Cleaning
• Sampling
• Analytical methods
• Process changes
• Deviations
• Complaints
• Validation activities

The objective is not to eliminate every theoretical risk.

The objective is to identify meaningful risks and establish appropriate controls.

PQR: Turning Historical Data Into Improvement

Looking at one batch can tell us what happened to that batch.

Looking at multiple batches over time can reveal something more valuable: trends.

Product Quality Review (PQR), or the equivalent periodic product-quality review required by a particular regulatory framework, provides an opportunity to evaluate accumulated information about a product and its manufacturing process.

Depending on the applicable system, this review may consider trends in areas such as:

• Deviations
• OOS/OOT results
• Complaints
• Changes
• Rejected batches
• Process performance
• Stability data
• CAPA
• Recurring quality issues

Process capability measures such as Ppk and Cpk, when appropriately applied to suitable data and process characteristics, can also help identify opportunities for improving process capability.

The important point is not the number itself.

A capability value becomes useful when it helps the quality and manufacturing teams understand process performance and decide whether improvement is needed.

This is where QC data becomes more than a release requirement.

Historical QC and process data can become a tool for improving the process that produces the medicine.

Pharmaceutical Quality Assurance vs Quality Control

QA and QC are closely connected, but they are not interchangeable terms.

Quality Control (QC) focuses heavily on sampling, testing, analytical evaluation, specifications, and the generation of objective quality data.

Quality Assurance (QA) is broader. It encompasses the systems and controls used to provide confidence that pharmaceutical products will consistently meet appropriate quality requirements.

A simplified way to look at the relationship is:

QC asks: “What does the data show?”

QA asks: “What system ensures that quality requirements are consistently achieved?”

In real pharmaceutical operations, the responsibilities are interconnected and the exact division of activities varies by organization and procedure.

Neither function can replace the other.

Where ICH Q10 Fits Into Pharmaceutical Quality

ICH Q10 provides a model for a Pharmaceutical Quality System (PQS) across the product lifecycle.

The framework connects pharmaceutical manufacturing with quality-system elements such as:

• Process performance and product quality monitoring
• Corrective and preventive action
• Change management
• Management responsibility
• Knowledge management
• Quality risk management

ICH Q10 also describes the relationship between the pharmaceutical quality system and commercial manufacturing activities including materials, facilities, equipment, production, quality control and assurance, release, storage, and distribution.

This broader view is important because pharmaceutical quality is not the responsibility of the QC laboratory alone.

It is a system-level responsibility.

How QC Data Can Improve Pharmaceutical Manufacturing

The strongest QC systems do more than release or reject batches.

They generate information that can help the organization understand its processes.

For example, repeated deviations may indicate a weakness that requires CAPA. An emerging analytical trend may indicate increasing process variation. A recurring OOT signal may deserve attention even before an OOS result occurs.

PQR can bring these individual observations together.

Process capability analysis can provide another perspective where statistically appropriate.

CAPA effectiveness checks can then determine whether implemented actions actually improved the situation.

This creates a cycle:

Measure → Evaluate → Investigate → Correct → Verify → Improve

That cycle is one of the practical ways a pharmaceutical quality system moves from simple compliance toward continual improvement.

Common Misunderstandings About Pharmaceutical QC

“A product passed QC, so the manufacturing process must be perfect.”

Not necessarily.

A passing result is important evidence that the tested sample met the applicable requirement. It does not eliminate the need for controlled manufacturing processes, validated methods, appropriate sampling, and GMP controls.

“The CoA proves that a raw-material supplier is reliable.”

Not by itself.

The CoA provides information about the tested material or batch. Supplier qualification evaluates the broader ability of the supplier to consistently provide acceptable material.

“An OOT result is not important because it is still within specification.”

An OOT result may identify an emerging trend that deserves evaluation. It does not automatically mean the product is unacceptable, but ignoring meaningful trends can allow process variation to develop unnoticed.

“CAPA is complete once the action is implemented.”

Implementation and effectiveness are different questions.

A CAPA should address the identified cause, and appropriate effectiveness verification may be needed to determine whether the problem has actually been controlled.

Frequently Asked Questions

What is pharmaceutical quality control? +

Pharmaceutical quality control is the part of pharmaceutical quality management concerned with sampling, specifications, testing, documentation, and evaluation of materials and products against established quality requirements.

What is QC testing in the pharmaceutical industry? +

QC testing in the pharmaceutical industry involves scientifically appropriate analysis of materials, in-process samples, finished products, stability samples, and other relevant samples to determine whether they meet defined requirements.

What is the difference between QA and QC? +

QC primarily generates and evaluates quality-related testing data, while QA encompasses the broader systems and controls used to ensure that pharmaceutical products are consistently produced and controlled according to applicable quality requirements.

Why is QC testing not enough to ensure pharmaceutical quality? +

Because final testing examines selected samples after manufacturing. It cannot by itself eliminate risks such as contamination, mix-ups, uncontrolled process variation, equipment problems, or weaknesses in manufacturing systems. WHO GMP specifically emphasizes controls throughout production rather than relying only on final-product testing.

What happens when a pharmaceutical QC test fails? +

An OOS result should be handled through the applicable approved investigation procedure. The investigation should determine whether the result is attributable to a laboratory issue, manufacturing-related factor, material issue, or another scientifically supported cause. Appropriate corrective action follows when a root cause is established.

What is ICH Q10? +

ICH Q10 is the ICH guideline describing a model for a Pharmaceutical Quality System across the product lifecycle. It connects quality-system elements such as process monitoring, CAPA, change management, and management responsibility with pharmaceutical manufacturing.

Bottom Line

Pharmaceutical quality control is essential, but quality cannot be created by laboratory testing alone.

A reliable medicine comes from a controlled system in which materials are appropriately qualified, equipment is suitable, processes are validated and monitored, analytical methods are reliable, personnel are trained, deviations are investigated, CAPA is effective, risks are managed, and historical data is used to improve process performance.

QC provides critical evidence.

QA provides the broader framework.

GMP provides essential manufacturing controls.

ICH quality guidelines provide internationally harmonized principles for development, risk management, and the pharmaceutical quality system.

The strongest pharmaceutical quality system brings all of these elements together.

A passing QC result matters—but it should be the evidence of a controlled process, not the substitute for one.

References

1. International Council for Harmonisation (ICH). Q8(R2): Pharmaceutical Development.
2. International Council for Harmonisation (ICH). Q9(R1): Quality Risk Management.
3. International Council for Harmonisation (ICH). Q10: Pharmaceutical Quality System.
4. World Health Organization (WHO). Good Manufacturing Practices for Pharmaceutical Products: Main Principles.
5. World Health Organization (WHO). Quality Assurance of Pharmaceuticals: A Compendium of Guidelines and Related Materials, Volume 2: Good Manufacturing Practices and Inspection.
6. Muhammad Johar Altaf Khan. Why Pharmaceutical Quality Cannot Be Tested Into a Product. Life Science Daily News, 2026. Expert-contributed article.

Medical Disclaimer: This article is intended for educational purposes and discusses pharmaceutical quality systems, manufacturing controls, and quality-control principles. It is not a substitute for applicable regulatory requirements, validated procedures, official GMP guidance, or professional regulatory advice.